Combined anti-microtubule therapy: A phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer

S. E. Soule, Kathy Miller, P. Porcu, R. Ansari, F. Fata, J. W. McClean, R. Zon, G. W. Sledge, Lawrence Einhorn

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Docetaxel and estramustine exert anti-tumor effects by inhibiting microtubule function. In vitro data suggest synergism with this combination. This phase II study evaluated the response rate and toxicity of docetaxel and estramustine in patients with metastatic breast cancer (MBC). Patients and Methods: Patients were treated with docetaxel 35 mg/m2 on day 2 and estramustine phosphate 280 mg p.o. tds days 1-3 weekly for 3 of 4 weeks, for a maximum of six treatment cycles. Results: Thirty-nine patients were enrolled between August 1999 and March 2001; 36 were eligible. Of 31 evaluable patients, responses were observed in 15 patients (47%); two patients (6%) obtained a complete response. Median time to treatment failure was 6 months; median survival was 1 year. Thromboembolic toxicity occurred in 11% of patients: three experienced deep venous thromboses and one had a fatal pulmonary embolism. Myelosuppression was minimal with this regimen. Conclusions: Despite modest activity in metastatic breast cancer, the toxicity observed with the combination of estramustine and docetaxel precludes the routine use of this combination in the treatment of breast cancer. Further studies using this compound in metastatic breast cancer are not warranted.

Original languageEnglish
Pages (from-to)1612-1615
Number of pages4
JournalAnnals of Oncology
Volume13
Issue number10
DOIs
StatePublished - Oct 1 2002

Fingerprint

docetaxel
Estramustine
Microtubules
Breast Neoplasms
Therapeutics
Treatment Failure
Pulmonary Embolism
Venous Thrombosis

Keywords

  • Docetaxel
  • Estramustine
  • Metastatic breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Combined anti-microtubule therapy : A phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer. / Soule, S. E.; Miller, Kathy; Porcu, P.; Ansari, R.; Fata, F.; McClean, J. W.; Zon, R.; Sledge, G. W.; Einhorn, Lawrence.

In: Annals of Oncology, Vol. 13, No. 10, 01.10.2002, p. 1612-1615.

Research output: Contribution to journalArticle

Soule, S. E. ; Miller, Kathy ; Porcu, P. ; Ansari, R. ; Fata, F. ; McClean, J. W. ; Zon, R. ; Sledge, G. W. ; Einhorn, Lawrence. / Combined anti-microtubule therapy : A phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer. In: Annals of Oncology. 2002 ; Vol. 13, No. 10. pp. 1612-1615.
@article{b7c7e88446b7467b9ff7eaf9ee981e52,
title = "Combined anti-microtubule therapy: A phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer",
abstract = "Background: Docetaxel and estramustine exert anti-tumor effects by inhibiting microtubule function. In vitro data suggest synergism with this combination. This phase II study evaluated the response rate and toxicity of docetaxel and estramustine in patients with metastatic breast cancer (MBC). Patients and Methods: Patients were treated with docetaxel 35 mg/m2 on day 2 and estramustine phosphate 280 mg p.o. tds days 1-3 weekly for 3 of 4 weeks, for a maximum of six treatment cycles. Results: Thirty-nine patients were enrolled between August 1999 and March 2001; 36 were eligible. Of 31 evaluable patients, responses were observed in 15 patients (47{\%}); two patients (6{\%}) obtained a complete response. Median time to treatment failure was 6 months; median survival was 1 year. Thromboembolic toxicity occurred in 11{\%} of patients: three experienced deep venous thromboses and one had a fatal pulmonary embolism. Myelosuppression was minimal with this regimen. Conclusions: Despite modest activity in metastatic breast cancer, the toxicity observed with the combination of estramustine and docetaxel precludes the routine use of this combination in the treatment of breast cancer. Further studies using this compound in metastatic breast cancer are not warranted.",
keywords = "Docetaxel, Estramustine, Metastatic breast cancer",
author = "Soule, {S. E.} and Kathy Miller and P. Porcu and R. Ansari and F. Fata and McClean, {J. W.} and R. Zon and Sledge, {G. W.} and Lawrence Einhorn",
year = "2002",
month = "10",
day = "1",
doi = "10.1093/annonc/mdf283",
language = "English",
volume = "13",
pages = "1612--1615",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Combined anti-microtubule therapy

T2 - A phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer

AU - Soule, S. E.

AU - Miller, Kathy

AU - Porcu, P.

AU - Ansari, R.

AU - Fata, F.

AU - McClean, J. W.

AU - Zon, R.

AU - Sledge, G. W.

AU - Einhorn, Lawrence

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Background: Docetaxel and estramustine exert anti-tumor effects by inhibiting microtubule function. In vitro data suggest synergism with this combination. This phase II study evaluated the response rate and toxicity of docetaxel and estramustine in patients with metastatic breast cancer (MBC). Patients and Methods: Patients were treated with docetaxel 35 mg/m2 on day 2 and estramustine phosphate 280 mg p.o. tds days 1-3 weekly for 3 of 4 weeks, for a maximum of six treatment cycles. Results: Thirty-nine patients were enrolled between August 1999 and March 2001; 36 were eligible. Of 31 evaluable patients, responses were observed in 15 patients (47%); two patients (6%) obtained a complete response. Median time to treatment failure was 6 months; median survival was 1 year. Thromboembolic toxicity occurred in 11% of patients: three experienced deep venous thromboses and one had a fatal pulmonary embolism. Myelosuppression was minimal with this regimen. Conclusions: Despite modest activity in metastatic breast cancer, the toxicity observed with the combination of estramustine and docetaxel precludes the routine use of this combination in the treatment of breast cancer. Further studies using this compound in metastatic breast cancer are not warranted.

AB - Background: Docetaxel and estramustine exert anti-tumor effects by inhibiting microtubule function. In vitro data suggest synergism with this combination. This phase II study evaluated the response rate and toxicity of docetaxel and estramustine in patients with metastatic breast cancer (MBC). Patients and Methods: Patients were treated with docetaxel 35 mg/m2 on day 2 and estramustine phosphate 280 mg p.o. tds days 1-3 weekly for 3 of 4 weeks, for a maximum of six treatment cycles. Results: Thirty-nine patients were enrolled between August 1999 and March 2001; 36 were eligible. Of 31 evaluable patients, responses were observed in 15 patients (47%); two patients (6%) obtained a complete response. Median time to treatment failure was 6 months; median survival was 1 year. Thromboembolic toxicity occurred in 11% of patients: three experienced deep venous thromboses and one had a fatal pulmonary embolism. Myelosuppression was minimal with this regimen. Conclusions: Despite modest activity in metastatic breast cancer, the toxicity observed with the combination of estramustine and docetaxel precludes the routine use of this combination in the treatment of breast cancer. Further studies using this compound in metastatic breast cancer are not warranted.

KW - Docetaxel

KW - Estramustine

KW - Metastatic breast cancer

UR - http://www.scopus.com/inward/record.url?scp=0036808986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036808986&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdf283

DO - 10.1093/annonc/mdf283

M3 - Article

C2 - 12377650

AN - SCOPUS:0036808986

VL - 13

SP - 1612

EP - 1615

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 10

ER -